Original ContributionProspective Randomized Phase III Trial of Etoposide/Cisplatin Versus High-Dose Epirubicin/Cisplatin in Small-Cell Lung Cancer
References (30)
Management of small-cell cancer of the lung
Lancet
(1992)- et al.
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis
Lung Cancer
(2000) - et al.
Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group
Eur J Cancer
(1992) - et al.
CALGB 9732: Final report of a Randomized phase III intergroup trial of etoposide (VP-16) and cisplatin (DDP) with or without paclitaxel (TAX) and G-CSF in patients with extensive stage small cell lung cancer (ED-SCLC)
Lung Cancer
(2003) - et al.
A randomized study of timing of thoracic irradiation in small cell lung cancer (SCLC)-study 8
Lung Cancer
(2003) - et al.
Small-cell lung cancer
Chest
(2003) - et al.
Cancer statistics
CA Cancer J Clin
(2002) - et al.
Twenty years of phase III trials for patients with extensive- stage small-cell lung cancer: perceptible progress
J Clin Oncol
(1999) - et al.
A meta-analysis of thoracic radiation therapy for small-cell lung cancer
N Engl J Med
(1992) - et al.
Does thoracic irradiation improve survival and local control in limited- stage small-cell carcinoma of the lung? A meta-analysis
J Clin Oncol
(1992)
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
J Clin Oncol
Randomized study of CODE versus alternating CAV/EP for extensive stage small-cell lung cancer: an Intergroup Study of the national cancer Institute of Canada Clinical trials Group and the Southwest Oncology Group
J Clin Oncol
Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
J Natl Cancer Inst
Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group
J Clin Oncol
Epirubicin: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer
Drugs
Cited by (32)
A systematic review of survival following anti-cancer treatment for small cell lung cancer
2020, Lung CancerCitation Excerpt :In total, we examined survival data from 22,528 people. Supplement 4 summarises the included manuscripts, 11 of which were abstracts [14–174]. The majority of manuscripts were observational cohort studies (100 (62.5 %)) and the remaining were randomized/non-randomized controlled trials (60 (37.5 %).
Treatment of Extensive-Stage Small Cell Lung Cancer
2018, IASLC Thoracic OncologyOlder cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer
2017, Cancer EpidemiologyCitation Excerpt :Most papers included a mean, median or a minimum – maximum age range, but some provided no mention of the age of participants at all. Upon further investigation, it appeared that these details were not simply lost in translation during the meta-analyses, but often failed to be included in the original articles selected for these reviews [19–59]. This is unfortunate because without the inclusion of the age distribution of participants in these original studies and subsequently in pooled or meta-analyses it is difficult to generalize findings to cancer patients of all ages.
Assessing the relative effectiveness and tolerability of treatments in small cell lung cancer: A network meta-analysis
2013, Cancer EpidemiologyCitation Excerpt :All regimens are listed in Supplementary Table 2. Sixteen treatments were compared directly with EP in 18 trials [20–37]: (1) Cyclophosphamide plus Doxorubicin (CAV); (2) Cisplatin plus Etoposide plus Ifosfamide (VIP); (3) Cyclophosphamide plus Doxorubicin plus Etoposide plus GCSF [ACE (intensified)]; (4) Cisplatin plus Epirubicin (PEP); (5) Cisplatin plus Topotecan (TC); (6) Cisplatin plus Etoposide/Cyclophosphamide plus Doxorubicin plus Vincristine (CAV/EP); (7) Cisplatin plus Etoposide plus GCSF [EP (intensified)]; (8) Carboplatin (AUC5) plus Etoposide (EC); (9) Carboplatin (AUC5) plus Gemcitabin (GEMCAR); (10) Cisplatin plus Irinotecan (IP); (11) Cisplatin plus Cyclophosphamide plus Etoposide plus Epirubicin (CCEE); (12) Cisplatin plus Etoposide plus Megestrol acetate (EP + Ma); (13) Cisplatin plus Etoposide plus natural interferon alpha (EP + nIFNA-a); (14) Cisplatin plus Etoposide plus recombinant interferon alpha (EP + rIFNA-a); (15) Etoposide plus Ifosfamide (IE) and 16) Cisplatin plus Etoposide plus Paclitaxel (PET). The numbers of direct comparisons with EP for the outcomes CR, ORR, NP and FNP were 18, 17, 9 and 1, respectively.
Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: Beyond traditional treatment approaches
2013, Journal of Thoracic OncologyCitation Excerpt :Overall, thalidomide was not associated with a significant improvement in survival, although there was some evidence of slower progression and longer survival in patients with a PS of 1 to 2.61 Another antiangiogenic agent, cediranib, was found to have no clinical activity in a phase II trial of patients with relapsed/recurrent SCLC as monotherapy.62 Just as marimastat was assessed in the first-line setting, another MMPI, BAY12-9566, was assessed in the second-line setting as adjuvant therapy for patients with SCLC.
Small lung cell cancer
2013, Medicine (Spain)
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cancer Information Group, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.